Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Wynzora Generic Name & Formulations
Legal Class
Rx
General Description
Calcipotriene 0.005% + betamethasone dipropionate 0.064%; crm.
Pharmacological Class
Vit. D3 derivative + topical steroid.
How Supplied
Crm—60g
Manufacturer
Generic Availability
NO
Wynzora Indications
Indications
Plaque psoriasis.
Wynzora Dosage and Administration
Adult
≥18yrs: apply to affected areas once daily for up to 8 weeks; max 100g per week. Discontinue when control is achieved. Do not occlude.
Children
<18yrs: not established.
Wynzora Contraindications
Not Applicable
Wynzora Boxed Warnings
Not Applicable
Wynzora Warnings/Precautions
Warnings/Precautions
Not for oral, ophthalmic, or intravaginal use. Avoid eyes, face, groin, axillae, or if skin atrophy is present at the treatment site. Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, or hyperglycemia occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Allergic contact dermatitis. Pregnancy. Nursing mothers.
Wynzora Pharmacokinetics
See Literature
Wynzora Interactions
Interactions
Systemic absorption potentiated by other corticosteroids.
Wynzora Adverse Reactions
Adverse Reactions
Upper respiratory infection, headache, application site irritation.
Wynzora Clinical Trials
See Literature
Wynzora Note
Not Applicable
Wynzora Patient Counseling
See Literature
Images
